William Allan Corp increased its stake in shares of West Pharmaceutical Services, Inc. (NYSE:WST - Free Report) by 112.4% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 7,000 shares of the medical instruments supplier's stock after purchasing an additional 3,705 shares during the period. William Allan Corp's holdings in West Pharmaceutical Services were worth $2,101,000 as of its most recent SEC filing.
Other institutional investors have also recently modified their holdings of the company. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in West Pharmaceutical Services by 21.8% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 683,350 shares of the medical instruments supplier's stock worth $205,114,000 after acquiring an additional 122,361 shares during the period. FMR LLC grew its stake in shares of West Pharmaceutical Services by 199.4% during the 3rd quarter. FMR LLC now owns 595,775 shares of the medical instruments supplier's stock valued at $178,828,000 after buying an additional 396,780 shares during the period. Kayne Anderson Rudnick Investment Management LLC grew its stake in shares of West Pharmaceutical Services by 6.8% during the 2nd quarter. Kayne Anderson Rudnick Investment Management LLC now owns 593,692 shares of the medical instruments supplier's stock valued at $195,556,000 after buying an additional 37,702 shares during the period. Charles Schwab Investment Management Inc. grew its stake in shares of West Pharmaceutical Services by 1.5% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 448,184 shares of the medical instruments supplier's stock valued at $134,527,000 after buying an additional 6,756 shares during the period. Finally, Champlain Investment Partners LLC grew its stake in shares of West Pharmaceutical Services by 29.7% during the 3rd quarter. Champlain Investment Partners LLC now owns 444,000 shares of the medical instruments supplier's stock valued at $133,271,000 after buying an additional 101,710 shares during the period. 93.90% of the stock is currently owned by institutional investors and hedge funds.
Insider Buying and Selling
In other news, VP Charles Witherspoon sold 703 shares of the company's stock in a transaction dated Tuesday, October 29th. The shares were sold at an average price of $310.40, for a total value of $218,211.20. Following the sale, the vice president now owns 1,253 shares in the company, valued at approximately $388,931.20. This represents a 35.94 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.53% of the stock is owned by corporate insiders.
West Pharmaceutical Services Trading Up 0.7 %
Shares of NYSE WST traded up $2.36 during trading on Friday, hitting $325.68. 305,786 shares of the company traded hands, compared to its average volume of 571,402. West Pharmaceutical Services, Inc. has a 1 year low of $265.00 and a 1 year high of $413.70. The company has a 50-day moving average price of $308.46 and a 200-day moving average price of $313.41. The firm has a market capitalization of $23.59 billion, a P/E ratio of 48.13, a P/E/G ratio of 24.42 and a beta of 1.00. The company has a quick ratio of 2.23, a current ratio of 3.00 and a debt-to-equity ratio of 0.07.
West Pharmaceutical Services (NYSE:WST - Get Free Report) last announced its quarterly earnings results on Thursday, October 24th. The medical instruments supplier reported $1.85 earnings per share for the quarter, topping analysts' consensus estimates of $1.50 by $0.35. West Pharmaceutical Services had a net margin of 17.37% and a return on equity of 18.41%. The firm had revenue of $746.90 million during the quarter, compared to analysts' expectations of $709.62 million. During the same period in the prior year, the company earned $2.16 EPS. The firm's revenue was down .1% on a year-over-year basis. On average, equities analysts predict that West Pharmaceutical Services, Inc. will post 6.67 EPS for the current year.
West Pharmaceutical Services Increases Dividend
The firm also recently declared a quarterly dividend, which was paid on Wednesday, November 20th. Investors of record on Wednesday, November 13th were given a dividend of $0.21 per share. This represents a $0.84 dividend on an annualized basis and a yield of 0.26%. This is a boost from West Pharmaceutical Services's previous quarterly dividend of $0.20. The ex-dividend date was Wednesday, November 13th. West Pharmaceutical Services's dividend payout ratio is 12.46%.
West Pharmaceutical Services Profile
(
Free Report)
West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.
Featured Articles
Before you consider West Pharmaceutical Services, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and West Pharmaceutical Services wasn't on the list.
While West Pharmaceutical Services currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
